NYSE · LLY
Eli Lilly and Company
$1,412.51+$38.81 (+2.83%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.56% below the high.
Loading market information…
OTC · HLTHQ · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Cue Health Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Cue Health Inc.’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of -$0.26. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Cue Health Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cue Health Inc. functioned as a healthcare technology company, developing the Cue Health platform to provide individuals and healthcare providers with convenient and personalized access to lab-quality diagnostic tests, usable both at home and at the point-of-care. The platform also enabled on-demand telehealth consultations and offered treatment options for various health and wellness needs. Its core offering, the Cue Integrated Care platform, comprised essential hardware components like the Cue Health Monitoring System (featuring a reusable Cue Reader, a single-use Cue Cartridge, and a Cue Wand), sophisticated software including the cloud-based Cue Data and Innovation Layer for analytics, and virtual care delivery applications such as the Cue Health App and Cue Enterprise Dashboard. The platform also integrated with a broader ecosystem, connecting to electronic medical record systems, pharmacies, last-mile delivery services, clinician networks, and laboratories. Additionally, the company supplied COVID-19 testing kits. Founded in 2010 in San Diego, California, the firm was formerly known as Cue Inc. until its name change in December 2017. However, on May 28, 2024, Cue Health Inc. and its affiliates initiated voluntary liquidation by filing for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 07:39 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2022 | Dec 31, 2022 | -$0.21+61.07% vs estimate | $146.78M+207.22% vs estimate |
|---|
| Q4 2021 | Sep 29, 2022 | -$0.45+17.58% vs estimate | $69.59M+19.64% vs estimate |
|---|
| Q2 2022 | Aug 10, 2022 | -$0.37+20.0% vs estimate | $87.70M+65.75% vs estimate |
|---|
THE ANALYST VIEW
1 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,412.51+$38.81 (+2.83%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.56% below the high.
$273.84-$1.36 (-0.49%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.91% below the high.
$293.72+$2.93 (+1.01%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.66% below the high.
$149.63+$3.30 (+2.26%)
Merck & Co., Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.62% below the high.
$406.61-$4.30 (-1.05%)
UnitedHealth Group Incorporated’s quoted price sits in the upper half of its reported 52-week range, 11.96% below the high.
$0.01$0.00 (0.0%)
Clever Leaves Holdings Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.2% below the high.
$0.00$0.00 (0.0%)
HTG Molecular Diagnostics, Inc.: Healthcare · Medical - Diagnostics & Research.
$0.00$0.00 (0.0%)
MedAvail Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
